Analyst Consensus ?
ConsensusHold42 ratings
Bullish1740.5%
Neutral2252.4%
Bearish37.1%
Zimmer Biomet Holdings, Inc. · ZBH · FY2026 Q3 · Calendar Q4 2026
Zimmer Biomet raises 2026 outlook as hip and technology growth offset knee weakness
Zimmer Biomet's raised full-year outlook and growth in hips, S.E.T. and technology & data point to resilient underlying demand. The case remains conditional on recovering the knee franchise and limiting China and cost headwinds.
Reported Before market openNYSEHealthcare
$18.51B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.88
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.04B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+14.6%
Event window
SPY move
+1.8%
Same window
Abnormal move
+12.8%
Stock minus SPY
Volume
1.6×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
ZBHSPY benchmark
Ask FN2 about ZBH FY2026 Q3
Transcript, numbers and history already loaded
What drove ZBH's +14.6% move after FY2026 Q3 earnings?What changed in ZBH's guidance and outlook in FY2026 Q3?Give me the bull and bear case for ZBH after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year organic constant-currency sales growth and adjusted EPS guidance. Q3 growth was led by hips and technology & data, while knee sales declined amid the sales-force transition. Management also moved the expected Monogram launch timeline forward to the first half of 2027.
Guidance delta
Raised full-year organic constant-currency sales growth guidance to 3–3.5% and adjusted EPS guidance to $8.50–$8.60.
Key takeaways
- Q3 net sales were reported at $2.63 billion, with 3.7% constant-currency growth.
- Hip growth and technology & data gains supported the quarter; the knee franchise declined 2.6% on a constant-currency basis.
- The sales-force specialization was 75% complete, but its effect on knee performance remains a key execution test.
- Paragon 28 growth and the planned Monogram launch broaden the product and technology pipeline.
Management priorities
- Complete the knee sales-force specialization and improve commercial execution.
- Advance the Monogram system toward the planned first-half 2027 launch.
- Expand robotics, navigation and recurring-revenue technology platforms.
- Continue manufacturing efficiency initiatives and selective strategic investment.
Follow ZBH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$110.15Current
$83Low
$118.98Average
$180High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 4, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Argus Research | Buy | Buy | Maintain | Oct 22, 2026 |
| Canaccord Genuity | Hold | Hold | Maintain | Aug 10, 2026 |
| Truist Securities | Hold | Hold | Maintain | Aug 7, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 6, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 6, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Aug 6, 2026 |
| BMO Capital | Market Perform | Outperform | Downgrade | Jul 9, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Citigroup | Neutral | Neutral | Maintain | May 28, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Apr 29, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Apr 29, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Apr 29, 2026 |
| Barclays | Underweight | Underweight | Maintain | Apr 29, 2026 |
| BTIG | Neutral | Buy | Downgrade | Mar 23, 2026 |
| Needham | Hold | Hold | Maintain | Feb 10, 2026 |
| UBS | Sell | Sell | Maintain | Jan 28, 2026 |
| Baird | Neutral | Outperform | Downgrade | Dec 16, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 8, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | May 7, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 6, 2025 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 6, 2025 |
| Oppenheimer | Outperform | Outperform | Maintain | Oct 15, 2024 |
| TD Cowen | Hold | Hold | Maintain | Sep 6, 2024 |
| Piper Sandler | Neutral | Overweight | Downgrade | Jul 1, 2024 |
| B of A Securities | Neutral | Underperform | Upgrade | May 3, 2023 |
| Jefferies | Hold | Underperform | Upgrade | Mar 31, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | May 4, 2022 |
| Loop Capital | Hold | Buy | Downgrade | Mar 2, 2022 |
| Deutsche Bank | Hold | Hold | Maintain | Feb 8, 2022 |
| Northland Capital Markets | Outperform | Market Perform | Upgrade | Apr 9, 2021 |
| Credit Suisse | Underperform | Underperform | Maintain | Nov 9, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 12, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Apr 28, 2020 |
| Argus | Buy | Hold | Upgrade | Aug 12, 2019 |
| Citi | Buy | Buy | Maintain | Aug 2, 2019 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 30, 2018 |
| Stifel Nicolaus | Buy | Hold | Upgrade | Jan 31, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Jan 31, 2018 |
| Edward Jones | Buy | Hold | Upgrade | Nov 9, 2017 |
| PiperJaffray | Neutral | Overweight | Downgrade | Nov 2, 2017 |
| Northcoast Research | Neutral | Buy | Downgrade | Nov 8, 2016 |
| Northland Securities | Perform | Outperform | Downgrade | Jan 7, 2016 |
Named analyst price targets
Upside is calculated against the persisted current price $110.15. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Canaccord Genuity | Caitlin Cronin | $100 | $96.55 | -9.2% | Aug 10, 2026 |
| Truist Financial | Analyst unavailable | $106 | $96.62 | -3.8% | Aug 6, 2026 |
| Robert W. Baird | Analyst unavailable | $104 | $97.32 | -5.6% | Aug 6, 2026 |
| UBS | Patrick Wood | $120 | $97.06 | +8.9% | Aug 6, 2026 |
| Bernstein | Analyst unavailable | $93 | $97.53 | -15.6% | Aug 6, 2026 |
| BMO Capital | Analyst unavailable | $96 | $98.16 | -12.8% | Aug 6, 2026 |
| RBC Capital | Kendall Au | $110 | $98.16 | -0.1% | Aug 6, 2026 |
| UBS | Patrick Wood | $115 | $92.07 | +4.4% | Jul 28, 2026 |
| BMO Capital | Analyst unavailable | $95 | $87.56 | -13.8% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $92 | $80.8 | -16.5% | Apr 29, 2026 |
| Canaccord Genuity | Analyst unavailable | $83 | $82.8 | -24.6% | Apr 29, 2026 |
| Stifel Nicolaus | Rick Wise | $105 | $82.8 | -4.7% | Apr 29, 2026 |
| Robert W. Baird | Analyst unavailable | $92 | $82.8 | -16.5% | Apr 29, 2026 |
| Barclays | Matt Miksic | $94 | $82.8 | -14.7% | Apr 29, 2026 |
| Barclays | Matt Miksic | $100 | $96.69 | -9.2% | Feb 12, 2026 |
| UBS | Analyst unavailable | $89 | $93.69 | -19.2% | Feb 11, 2026 |
| UBS | Analyst unavailable | $86 | $85.27 | -21.9% | Jan 28, 2026 |
| Bernstein | Analyst unavailable | $99 | $94.08 | -10.1% | Jan 9, 2026 |
| Goldman Sachs | David Roman | $93 | $94.08 | -15.6% | Jan 9, 2026 |
| Evercore ISI | Analyst unavailable | $120 | $90.02 | +8.9% | Jan 5, 2026 |
| Robert W. Baird | Jeff Johnson | $100 | $92.52 | -9.2% | Dec 16, 2025 |
| Stifel Nicolaus | Rick Wise | $110 | $87.91 | -0.1% | Nov 5, 2025 |
| Johnson Rice | Analyst unavailable | $112 | $88.05 | +1.7% | Nov 5, 2025 |
| Barclays | Analyst unavailable | $105 | $103.18 | -4.7% | Nov 5, 2025 |
| BTIG | Ryan Zimmerman | $122 | $94.71 | +10.8% | Oct 13, 2025 |
| RBC Capital | Analyst unavailable | $111 | $95.52 | +0.8% | Oct 10, 2025 |
| Stifel Nicolaus | Analyst unavailable | $118 | $100.36 | +7.1% | Sep 19, 2025 |
| Redburn Partners | Ed Ridley-Day | $130 | $100.21 | +18.0% | Sep 18, 2025 |
| UBS | Danielle Antalffy | $96 | $97.94 | -12.8% | Aug 8, 2025 |
| Truist Financial | Richard Newitter | $101 | $92.27 | -8.3% | May 6, 2025 |
| RBC Capital | Shagun Singh | $112 | $92.27 | +1.7% | May 6, 2025 |
| Stifel Nicolaus | Rick Wise | $115 | $90.48 | +4.4% | May 6, 2025 |
| Wells Fargo | Larry Biegelsen | $98 | $90.48 | -11.0% | May 5, 2025 |
| Truist Financial | Richard Newitter | $117 | $106.92 | +6.2% | Oct 31, 2024 |
| Oppenheimer | Steven Lichtman | $135 | $104.83 | +22.6% | Oct 15, 2024 |
| BTIG | Ryan Zimmerman | $126 | $105.69 | +14.4% | Oct 3, 2024 |
| Evercore ISI | Vijay Kumar | $110 | $107.95 | -0.1% | Oct 1, 2024 |
| Truist Financial | Richard Newitter | $112 | $105.14 | +1.7% | Sep 13, 2024 |
| Canaccord Genuity | Caitlin Cronin | $115 | $104.83 | +4.4% | Sep 10, 2024 |
| Raymond James | Jayson Bedford | $128 | $107.09 | +16.2% | Aug 8, 2024 |
| Oppenheimer | Steven Lichtman | $145 | $105.81 | +31.6% | Aug 8, 2024 |
| Stifel Nicolaus | Rick Wise | $130 | $107.5 | +18.0% | Aug 7, 2024 |
| Morgan Stanley | Drew Ranieri | $120 | $108.69 | +8.9% | Jul 15, 2024 |
| Piper Sandler | Matt O'Brien | $115 | $108.53 | +4.4% | Jul 1, 2024 |
| Piper Sandler | Matthew O\'Brien | $140 | $114.44 | +27.1% | May 31, 2024 |
| RBC Capital | Shagun Singh | $140 | $115.14 | +27.1% | May 30, 2024 |
| BTIG | Ryan Zimmerman | $139 | $116.41 | +26.2% | May 28, 2024 |
| Argus Research | David Toung | $150 | $119.05 | +36.2% | May 21, 2024 |
| Truist Financial | Analyst unavailable | $137 | $128.46 | +24.4% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $140 | $128.82 | +27.1% | Feb 6, 2023 |
| RBC Capital | Analyst unavailable | $141 | $125.7 | +28.0% | Jan 9, 2023 |
| Morgan Stanley | Analyst unavailable | $135 | $126.77 | +22.6% | Jan 6, 2023 |
| Truist Financial | Analyst unavailable | $135 | $124.91 | +22.6% | Dec 20, 2022 |
| Citigroup | Analyst unavailable | $130 | $125.36 | +18.0% | Dec 12, 2022 |
| Wells Fargo | Larry Biegelsen | $124 | $115.33 | +12.6% | Nov 23, 2022 |
| Stifel Nicolaus | Analyst unavailable | $120 | $104.62 | +8.9% | Jul 18, 2022 |
| RBC Capital | Analyst unavailable | $128 | $122.2 | +16.2% | May 4, 2022 |
| Piper Sandler | Matt O'Brien | $130 | $121.37 | +18.0% | May 3, 2022 |
| Bank of America Securities | Travis Steed | $120 | $122.13 | +8.9% | Mar 3, 2022 |
| JMP Securities | David Turkaly | $145 | $116.08 | +31.6% | Feb 8, 2022 |
| RBC Capital | Shagun Singh Chadha | $125 | $116.08 | +13.5% | Feb 8, 2022 |
| Truist Financial | Samuel Brodovsky | $128 | $116.08 | +16.2% | Feb 8, 2022 |
| Canaccord Genuity | Kyle Rose | $125 | $108.13 | +13.5% | Feb 7, 2022 |
| Deutsche Bank | Pito Chickering | $121 | $108.13 | +9.9% | Feb 7, 2022 |
| Leerink Partners | Danielle Antalffy | $135 | $108.13 | +22.6% | Feb 7, 2022 |
| Piper Sandler | Matthew O'Brien | $110 | $108.13 | -0.1% | Feb 7, 2022 |
| Robert W. Baird | Jeff Johnson | $138 | $108.13 | +25.3% | Feb 7, 2022 |
| Needham | Michael Matson | $143 | $108.13 | +29.8% | Feb 7, 2022 |
| Cowen & Co. | Josh Jennings | $140 | $119.14 | +27.1% | Jan 20, 2022 |
| Motley Fool | Anders Bylund | $140 | $121.23 | +27.1% | Dec 9, 2021 |
| Jefferies | Anthony Petrone | $175 | $136.9 | +58.9% | Nov 5, 2021 |
| Guggenheim | Christopher Pasquale | $180 | $136.9 | +63.4% | Nov 5, 2021 |
| Evercore ISI | Vijay Kumar | $170 | $133.13 | +54.3% | Nov 4, 2021 |
| Oppenheimer | Steven Lichtman | $190 | $143.03 | +72.5% | Aug 4, 2021 |
Track every rating change on ZBH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationZimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Historical context
All ZBH earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RPRX Royalty Pharma plc | FY2026 Q3 · Calendar Q4 2026 | — | +1.4% | Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand |
| MDLN Medline Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +16.2% | Medline Raises 2026 Organic Sales Outlook on 10% Q3 Growth |
| NVO Novo Nordisk A/S | FY2026 Q3 · Calendar Q4 2026 | — | +6.4% | Novo Nordisk Q3: obesity demand supports growth, pricing and LOE remain risks |
| CRL Charles River Laboratories International, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -6.0% | Charles River raises FY2026 outlook after strong Q3; demand and margins improve |
| UTHR United Therapeutics Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +0.6% | United Therapeutics’ record quarter highlights Tyvaso growth and pipeline execution |
| AMGN Amgen Inc. | FY2026 Q3 · Calendar Q4 2026 | +11.4% | +1.6% | Amgen Q3: Growth Drivers, Pipeline Progress and Higher 2026 Guidance |
Latest beats and misses
Who reports nextBeat on EPS
- IFFFY2026 Q3 · November 3, 2026+2.1% EPS-4.9% move
- JKHYFY2027 Q1 · November 3, 2026+10.1% EPS+10.8% move
- HL-PBFY2026 Q3 · November 3, 2026+54.0% EPS— move
- SUFY2026 Q3 · November 3, 2026+20.9% EPS-4.5% move
- AFGFY2026 Q3 · November 3, 2026+4.5% EPS+1.0% move
- WTRGFY2026 Q3 · November 3, 2026+13.7% EPS+2.5% move
Missed on EPS
- OHIFY2026 Q3 · November 3, 2026-42.5% EPS+3.5% move
- MOSFY2026 Q3 · November 3, 2026-1656.0% EPS+17.4% move
- OVVFY2026 Q3 · November 3, 2026-2.0% EPS-5.1% move
- BSACFY2026 Q3 · October 30, 2026-20.0% EPS-3.0% move
- TXFY2026 Q3 · November 3, 2026-24.9% EPS-0.0% move
- CHTFY2026 Q3 · November 4, 2026-55.7% EPS+0.9% move
Get the ZBH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-04T18:11:14.258680+00:00
- FN2 earnings calendar · 2026-11-04T01:23:13.345574+00:00
- Polygon adjusted daily market bars · 2026-11-04T20:00:48.141798+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T20:00:48.139086+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.